SYNTHETIC BIOLOGY - A GLOBAL MARKET REPORT   

Research Abstract

This report analyzes the Global market for Synthetic Biology in US$ Million by the following three important application areas: Energy & Chemicals, Biotechnology & Pharmaceuticals, and Research & Development. Annual estimates and forecasts are provided for the period 2006 through 2015. The report profiles 51 companies including many key and niche players such as Amyris Biotechnologies, Inc., ATG Biosynthetics GmbH, Blue Heron Biotechnology, Inc., BP Plc, Chromatin Inc., DNA2.0, Draths Corp., febit Synbio GmbH, GENEART AG, GenScript USA, Inc., Gevo, Inc., Joule Biotechnologies, Inc., LC Sciences, LS9, Inc., OPXBIO Inc., Solazyme, Inc., Sloning BioTechnology GmbH, Synthetic Genomics, Inc., and Verdezyne, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Code : MCP-6581
Price : $3950
Companies : 51
Pages : 261
Date : July 2010
Market Data Tables : 69

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2  
   Data Interpretation & Reporting Level.....I-3
Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
  
   Synthetic Biology - An Overview.....II-1
Current & Future Analysis.....II-1
Market Scenario.....II-1
1$100
   Food and Other Basic Needs’ Scarcity to Fuel Synthetic Biology Market.....II-2
Food, Water, and Energy Statistics.....II-2
Future Outlook.....II-2
1$100
   Synthetic Biology – An Emerging Discipline.....II-31$100
   Synthetic Biology - Challenges.....II-4
Contribution of Synthetic Biology to Biotech.....II-4
Key developments in the Synthetic Biology Field:.....II-4
1$100
   Systems Biology Leading to Advancements in Synthetic Biology.....II-5
US and Europe - Propelling Research in the Field of Synthetic Biology.....II-5
Research in the US.....II-5
1$100
   Research in Europe.....II-61$100
   Scotland – R&D Scenario.....II-7
State of Synthetic Biology Research In the UK.....II-7
1$100
   International Genetically Engineered Machine (IGEM) – A Platform for
  Innovations.....II-8
1$100
   Introduction.....II-9
Historical Background.....II-9
Synthetic Biology Vis-à-vis Genetic Engineering - A Comparison.....II-9
1$100
   Scope of Synthetic Biology in Various Fields.....II-10
Engineering.....II-10
Chemistry.....II-10
Major Enabling Technologies.....II-10
Sequencing.....II-10
1$100
   Fabrication.....II-11
Modeling.....II-11
Measurement.....II-11
Market Potential.....II-11
Pharmaceutical.....II-11
Industrial.....II-11
Agriculture.....II-11
Life Sciences Research.....II-11
Renewable Energy.....II-11
1$100
   Potential Uses.....II-12
Biomedicine.....II-12
Intricate Molecular Devices Utilized for Tissue Regeneration/Repair.....II-12
Smart Drugs.....II-12
Biological Delivery Systems.....II-12
Vectors for Therapy.....II-12
1$100
   Personalized Medicine.....II-13
Cells with Novel Properties for Betterment of Human Health.....II-13
In Vivo Synthesis of Small-Molecule Pharmaceuticals.....II-13
Intricate Natural Products.....II-13
Expansion of Chemistry of Life.....II-13
1$100
   Expanding Genetic Alphabet.....II-14
Nucleic Acids.....II-14
Proteins.....II-14
New Imaging and Targeting Methods.....II-14
Chemical Industry Sustainability.....II-14
Eco-friendly Production of Chemicals.....II-14
1$100
   Energy and Environment.....II-15
Bioremediation.....II-15
Energy Production.....II-15
Biomaterials and Smart Materials Production.....II-15
Synthesis.....II-15
Organization.....II-15
1$100
   Socio-Economic Concerns and Risks.....II-16
Production of Bio-Weapons.....II-16
Accidental Release.....II-16
Return on Investment.....II-16
Dissonance with Other Disciplines.....II-16
Continuous Evolution.....II-16
Curtailed Understanding.....II-16
1$100
   Unpredictable Ecosystem Effects.....II-17
Unexpected Transfer of Genes.....II-17
Aggravating Problems.....II-17
Lack of Regulatory Framework.....II-17
Industry Associations.....II-17
Synthetic Biology Industry Association (SynBIA).....II-17
1$100
   Industry Association of Synthetic Biology (IASB).....II-18
Researchers at JCVI Make Novel Advances in Synthetic Genomics.....II-18
2$200
   454 Life Sciences to Introduce GS Junior System and Improve Genome Sequencer FLX
  System.....II-20
DNA2.0 Launches pJexpress.....II-20
febit Introduces miRBase 14.0-based miRNA Biochip.....II-20
1$100
   Codexis Launches CodexTM MicroCyp Plate.....II-21
GeneWorks Expands Genome Analysis Services.....II-21
1$100
   Amyris Brasil Inks Agreements with Acucar Guarani, Bunge and Cosan Group.....II-22
Amyris Brasil Inaugurates Demonstration Facility.....II-22
Amyris Biotechnologies to Acquire Stake in Boa Vista Mill from São Martinho
  Group.....II-22
1$100
   Synthetic Genomics Inks Agreement with ExxonMobil Research and Engineering
  Company.....II-23
Verdezyne Inks Agreement with Novozymes.....II-23
Verdezyne Collaborates with Genencor.....II-23
1$100
   OneWorld Health, Sanofi-aventis and Amyris Biotechnologies Enter into
  Partnership.....II-24
Amyris Biotechnologies Enters into Partnership with Crystalsev.....II-24
1$100
   GENEART Extends Partnership with QIAGEN.....II-25
LC Sciences and DNAVision Enter into Strategic Marketing Alliance.....II-25
1$100
   Amyris Biotechnologies, Inc. (US).....II-26
ATG Biosynthetics GmbH (Germany).....II-26
Blue Heron Biotechnology, Inc. (US).....II-26
BP Plc. (UK).....II-26
1$100
   Chromatin Inc. (US).....II-27
DNA2.0 (US).....II-27
Draths Corp. (US).....II-27
1$100
   febit Synbio GmbH (Germany).....II-28
GENEART AG (Germany).....II-28
GenScript USA, Inc. (US).....II-28
Gevo, Inc. (US).....II-28
1$100
   Joule Biotechnologies, Inc. (US).....II-29
LC Sciences (US).....II-29
LS9, Inc. (US).....II-29
1$100
   OPXBIO Inc. (US).....II-30
Solazyme, Inc. (US).....II-30
Sloning BioTechnology GmbH (Germany).....II-30
1$100
   Synthetic Genomics, Inc. (US).....II-31
Verdezyne, Inc. (US).....II-31
1$100
   Table 1: World Recent Past, Current and Future Analysis for Synthetic Biology by End-Use Sector - Energy & Chemicals, Biotechnology & Pharmaceuticals, and Research & Development Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-321$300
   Table 2: World 10-Year Perspective for Synthetic Biology by End-Use Sector – Percentage Breakdown of Dollar Sales for Energy & Chemicals, Biotechnology & Pharmaceuticals, and Research & Development Markets for Years 2006, 2009 and 2015 (includes corresponding Graph/Chart).....II-331$300
  
Total Companies Profiled: 51 (including Divisions/Subsidiaries - 52)

Region/Country Players

The United States 37 Canada 1 Europe 11 France 1 Germany 5 The United Kingdom 3 Rest of Europe 2 Asia-Pacific (Excluding Japan) 2 Latin America 1
Click here to request a full table of contents and more details on this project.